Who owns Kailera Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KLRA from SEC Form 13F filings across 132 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 132 institutions disclosed 119.7M shares of Kailera Therapeutics, Inc. worth $1.37B — about 92.3% of shares outstanding; the largest disclosed holder is Bain Capital Investors LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
132
13F holders
$1.37B
value, 2026 filers
92.3%
of shares outstanding (119.7M sh)
49
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of KLRA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Investors LLC | 26.3M | $299.8M | 6.3% | 20.3% | 0.0% |
| 2 | Bain Capital Life Sciences Investors, LLC | 22.6M | $257.9M | 17.3% | 17.4% | 0.0% |
| 3 | RTW INVESTMENTS, LP | 10.8M | $123.1M | 1.2% | 8.3% | 0.0% |
| 4 | CANADA PENSION PLAN INVESTMENT BOARD | 7.3M | $83.4M | 0.0% | 5.6% | 0.0% |
| 5 | Atlas Venture Life Science Advisors, LLC | 5.2M | $59.1M | 9.4% | 4% | 0.0% |
| 6 | FMR LLC | 4.7M | $53.2M | 0.0% | 3.6% | +17.4% |
| 7 | BlackRock, Inc. | 4.6M | $52.2M | 0.0% | 3.5% | +16.4% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.2M | $47.7M | 0.1% | 3.2% | +30.1% |
| 9 | CITADEL ADVISORS LLC | 3.6M | $41.7M | 0.0% | 2.8% | +12.6% |
| 10 | Royalty Pharma Sub-Manager, LLC | 2.5M | $28.0M | 14.3% | 1.9% | 0.0% |
| 11 | STATE STREET CORP | 2.2M | $25.6M | 0.0% | 1.7% | +158.2% |
| 12 | Siren, L.L.C. | 2.2M | $25.3M | 0.6% | 1.7% | 0.0% |
| 13 | AMERIPRISE FINANCIAL INC | 2.1M | $23.9M | 0.0% | 1.6% | +155.0% |
| 14 | VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $19.2M | 0.0% | 1.3% | -0.7% |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $18.5M | 0.0% | 1.2% | -2.0% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $13.8M | 0.0% | 0.9% | +6.5% |
| 17 | Frazier Life Sciences Management, L.P. | 1.2M | $13.7M | 0.3% | 0.9% | +9.1% |
| 18 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 1.1M | $12.6M | 0.1% | 0.8% | 0.0% |
| 19 | Trails Edge Capital Partners, LP | 942,953 | $10.8M | 1.5% | 0.7% | -4.2% |
| 20 | MARSHALL WACE, LLPNEW | 878,196 | $10.0M | 0.0% | 0.7% | new |
| 21 | MILLENNIUM MANAGEMENT LLCNEW | 858,972 | $9.8M | 0.0% | 0.7% | new |
| 22 | GOLDMAN SACHS GROUP INC | 696,577 | $8.0M | 0.0% | 0.5% | +65.4% |
| 23 | PRICE T ROWE ASSOCIATES INC /MD/ | 631,951 | $7.2M | 0.0% | 0.5% | -82.1% |
| 24 | Vestal Point Capital, LP | 625,000 | $7.1M | 0.2% | 0.5% | +8.7% |
| 25 | UBS Group AG | 469,584 | $5.4M | 0.0% | 0.4% | -51.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.